Article Text

Download PDFPDF

Original article
MicroRNAs interfere with DNA methylation in rheumatoid arthritis synovial fibroblasts
  1. Niharika Gaur1,
  2. Emmanuel Karouzakis1,
  3. Selene Glück1,
  4. Edvardas Bagdonas2,
  5. Astrid Jüngel1,
  6. Beat A Michel1,
  7. Renate E Gay1,
  8. Steffen Gay1,
  9. Mojca Frank-Bertoncelj1 and
  10. Michel Neidhart1
  1. 1Centre of Experimental Rheumatology, University Hospital, Zurich, Switzerland
  2. 2Department of Regenerative Medicine, State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania
  1. Correspondence to Professor Michel Neidhart; michel.neidhart{at}usz.ch

Abstract

Background The DNA of rheumatoid arthritis synovial fibroblasts (RASF) is globally hypomethylated; this contributes to an aggressive behaviour. In an attempt to remethylate these cells, we supplemented with methyl donors. We investigated the possible interference of microRNAs (miRs).

Material and methods RASF were treated with L-methionine or betaine. Transcripts of de novo methyltransferases (DNMTs) and miRs were measured by real-time PCR, and a transcription PCR array was performed. Levels of homocysteine, matrix metalloproteinase-1 (MMP-1) and global DNA methylation were determined. Transfection with lipofectamine was performed with specific pre-miRs and anti-miRs, such as miR29 and let7f.

Results L-methionine was more efficient to increase DNA methylation than betaine. This was associated with a reduced expression of DNMT3A mRNA in betaine-treated RASF. Betaine increases the expression of miR29 in RASF which targets DNMT3A, thereby limiting the remethylation process. Nevertheless, betaine inhibited the expression of multiple transcription factors, decreased the release of MMP-1, biosynthesis of homocysteine and cell migration.

Conclusion Alterations in cellular miRs profiles, in particular the upregulation of miR29, which targets DNMT3A, may limit the efficiency of betaine if it is used as DNA remethylating agent. However, L-methionine also has similar impact on miR29 expression. On the other hand, betaine has multiple other beneficial effects on the activated phenotype of RASF; it is not excluded that the effect of betaine on DNMT3A is, at least in part, indirect. Clinical trials with betaine could be promising.

  • Rheumatoid Arthritis
  • Synovitis
  • Pharmacogenetics
  • Fibroblasts

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • NG and EK share first authorship.

  • Contributors Data were acquired by NG, EK, SG and EB. AJ, MF-B and MN analysed the results. Analysis of figures and statistics was performed by MN. BAM accomplished clinical organisation, patient samples, reading and correcting the manuscript. NG, EK and MN wrote the manuscript. AJ, MF-B, REG and SG read and corrected the manuscript. The work was founded by AJ, MN, REG, SG. All authors finally approved the manuscript.

  • Funding Baugarten Foundation (Zurich, Switzerland).

  • Competing interests None declared.

  • Patient consent Obtained.

  • Ethics approval The procedure was approved by the Ethics Committee of the University Hospital Zurich, and canton of Zurich, Switzerland.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement Data set will be available from the Dryad repository at http://datadryad.org/